Status:
RECRUITING
Efficacy and Safety of Secukinumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa
Lead Sponsor:
Peking Union Medical College
Conditions:
Hidradenitis Suppurativa (HS)
Hidradenitis Suppurativa (Acne Inversa)
Eligibility:
All Genders
Up to 80 years
Brief Summary
This study aims to retrospectively analyze the efficacy and safety of secukinumab combined with surgery in treating moderate to severe HS in real-world clinical practice, providing clinical practioner...
Detailed Description
Hidradenitis suppurativa (HS) is a chronic, recurrent, and disabling inflammatory disease that occurs in apocrine distribution sites such as the axilla, groin, and perianal region with a worldwide pre...
Eligibility Criteria
Inclusion
- Patients aged 18 to 80 years old with moderate-severe (Hurley II-III) HS
- The diagnosis of HS was confirmed by histopathological examination in the Department of Pathology of our hospital
- Patients with HS who received secukinumab combined with surgery in the Department of Dermatologic Surgery of our hospital
- Patients with complete clinical data followed up for at least 1 year
Exclusion
- Patients lost to follow-up
- Patients with less than one year of follow-up
- Patients who received additional adjuvant therapy during the follow-up period
Key Trial Info
Start Date :
January 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 21 2025
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06926192
Start Date
January 1 2020
End Date
June 21 2025
Last Update
April 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Science and Peking Union Medical College
Nanjing, Jiangsu, China, 210042